TARRYTOWN, N.Y. – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
Investors and the public can access the presentation via the “Investors & Media” section of Regeneron’s website: http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be available on the company website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company focused on inventing, developing, and commercializing transformative medicines for serious diseases. Founded and led by physician-scientists, the company leverages its proprietary technologies, including VelociSuite®, to develop optimized fully human antibodies and novel bispecific antibodies.
Regeneron is advancing medicine in multiple therapeutic areas, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic conditions, neurological and hematologic diseases, infectious diseases, and rare disorders. Through data-driven insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, the company identifies innovative targets to potentially treat or cure diseases.
By
